Newronika is a leading brand in the field of neural devices, specializing in transforming cutting-edge research into clinical therapies. As a spin-off company of the prestigious Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan, Newronika brings together a multidisciplinary team of experts from various neuroscience research groups. Their team comprises scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies.

With a focus on developing advanced technologies, Newronika aims to revolutionize the way neurological conditions, specifically Parkinson's disease, are treated. The brand's flagship product is the AlphaDBS, a closed-loop deep brain neuromodulation system. This innovative device is designed to offer personalized adaptive deep brain stimulation to manage symptoms associated with Parkinson's disease.

Newronika has successfully secured significant funding, including a 2. 5 million euros grant from the European Innovation Council, to conduct pivotal clinical trials in Europe. Newronika is committed to advancing the field of neuromodulation through collaboration and welcomes research collaborations to explore new applications for their technology.

With their headquarters in Milan, Italy, and a manufacturing location in Goose Creek, South Carolina, Newronika is poised to make a profound impact on the lives of patients worldwide